These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32161240)

  • 1. [Pretreatment screening for inflammatory bowel diseases;significance and problems in genotyping of NUDT15].
    Kakuta Y; Kinouchi Y; Masamune A
    Nihon Shokakibyo Gakkai Zasshi; 2020; 117(3):195-207. PubMed ID: 32161240
    [No Abstract]   [Full Text] [Related]  

  • 2. NUDT15: a novel player in thiopurine metabolism.
    Meijer B; Mulder CJ; de Boer NK
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):261-2. PubMed ID: 27308664
    [No Abstract]   [Full Text] [Related]  

  • 3. High-resolution melt analysis enables simple genotyping of complicated polymorphisms of codon 18 rendering the NUDT15 diplotype.
    Kakuta Y; Izumiyama Y; Okamoto D; Nakano T; Ichikawa R; Naito T; Moroi R; Kuroha M; Kanazawa Y; Kimura T; Shiga H; Kudo H; Minegishi N; Kawai Y; Tokunaga K; Nagasaki M; Kinouchi Y; Suzuki Y; Masasmune A;
    J Gastroenterol; 2020 Jan; 55(1):67-77. PubMed ID: 31641873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease.
    Asada A; Nishida A; Shioya M; Imaeda H; Inatomi O; Bamba S; Kito K; Sugimoto M; Andoh A
    J Gastroenterol; 2016 Jan; 51(1):22-9. PubMed ID: 26590936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
    Kakuta Y; Kawai Y; Okamoto D; Takagawa T; Ikeya K; Sakuraba H; Nishida A; Nakagawa S; Miura M; Toyonaga T; Onodera K; Shinozaki M; Ishiguro Y; Mizuno S; Takahara M; Yanai S; Hokari R; Nakagawa T; Araki H; Motoya S; Naito T; Moroi R; Shiga H; Endo K; Kobayashi T; Naganuma M; Hiraoka S; Matsumoto T; Nakamura S; Nakase H; Hisamatsu T; Sasaki M; Hanai H; Andoh A; Nagasaki M; Kinouchi Y; Shimosegawa T; Masamune A; Suzuki Y;
    J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
    Kang B; Kim TJ; Choi J; Baek SY; Ahn S; Choi R; Lee SY; Choe YH
    Aliment Pharmacol Ther; 2020 Aug; 52(3):459-470. PubMed ID: 32598049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the threshold of personalized medicine in inflammatory bowel disease: Next generation genetic predictors.
    Parkes M
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():5-6. PubMed ID: 30187553
    [No Abstract]   [Full Text] [Related]  

  • 8. NUDT15 genotype testing in inflammatory bowel disease patients in Australia.
    Yu N; Segal JP; Ding NS
    Intern Med J; 2022 Nov; 52(11):2016-2017. PubMed ID: 36404115
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine.
    Akiyama S; Matsuoka K; Fukuda K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Motobayashi M; Suzuki K; Takenaka K; Fujii T; Saito E; Nagahori M; Ohtsuka K; Mochizuki M; Watanabe M; Hashiguchi M; Kanai T
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1751-1757. PubMed ID: 31045285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
    Banerjee R; Ravikanth VV; Pal P; Bale G; Avanthi US; Goren I; Girish BG; Mitnala S; Reddy DN
    Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1683-1694. PubMed ID: 33111378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined or High Dose Immunosuppression in Inflammatory Bowel Disease patients who are NUDT15 Homozygous Harbors Risk of Developing Invasive Fungal Infections: A Case Series.
    Thomas DM; Mundhra SK; Prasad S; Swaroop S; Arora U; Ahmed S; Bhalla AS; Sharma R; Das P; Kedia S; Ahuja V
    Inflamm Bowel Dis; 2024 Sep; 30(9):1623-1625. PubMed ID: 38757903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Bowel Disease - From Bench to Bedside.
    Fichna J
    Curr Drug Targets; 2020; 21(14):1396. PubMed ID: 33100198
    [No Abstract]   [Full Text] [Related]  

  • 13. Update on thiopurine pharmacogenetics in inflammatory bowel disease.
    Roberts RL; Barclay ML
    Pharmacogenomics; 2015 Jul; 16(8):891-903. PubMed ID: 26067482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients.
    van Dieren JM; van Vuuren AJ; Kusters JG; Nieuwenhuis EE; Kuipers EJ; van der Woude CJ
    Gut; 2005 Nov; 54(11):1664. PubMed ID: 16227370
    [No Abstract]   [Full Text] [Related]  

  • 15. Do ITPA and TPMT genotypes predict the development of side effects to AZA?
    Duley JA; Marinaki AM; Arenas M; Florin TH
    Gut; 2006 Jul; 55(7):1048; author reply 1048-9. PubMed ID: 16766757
    [No Abstract]   [Full Text] [Related]  

  • 16. New directions and new strategies in inflammatory bowel diseases.
    Allez M; Lémann M
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S121-2. PubMed ID: 20117334
    [No Abstract]   [Full Text] [Related]  

  • 17. Inflammatory bowel disease.
    Sutherland LR
    Med Sect Proc; 1990; ():109-23. PubMed ID: 2103941
    [No Abstract]   [Full Text] [Related]  

  • 18. NUDT15 R139C variation increases the risk of azathioprine-induced toxicity in Chinese subjects: Case report and literature review.
    Fei X; Shu Q; Hua BZ; Wang SY; Chen ZY; Ge WH; Fang Y
    Medicine (Baltimore); 2018 Apr; 97(17):e0301. PubMed ID: 29702976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction: new approaches to the detection and management of inflammatory bowel disease: from genetic testing to treatment strategies.
    Gassull MA; Obrador A
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():1. PubMed ID: 16961736
    [No Abstract]   [Full Text] [Related]  

  • 20. TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects.
    Steponaitiene R; Kupcinskas J; Survilaite S; Varkalaite G; Jonaitis L; Kiudelis G; Denapiene G; Valantinas J; Skieceviciene J; Kupcinskas L
    Adv Med Sci; 2016 Mar; 61(1):135-40. PubMed ID: 26674571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.